Skip to Content
Merck
CN

CDR2 antigen and Yo antibodies.

Cancer immunology, immunotherapy : CII (2010-11-17)
Cecilie Totland, Nina K Aarskog, Tilo W Eichler, Mette Haugen, Jane K Nøstbakken, Sissel E Monstad, Helga B Salvesen, Sverre Mørk, Bjørn I Haukanes, Christian A Vedeler
ABSTRACT

Paraneoplastic cerebellar degeneration (PCD) is often associated with Yo antibodies that are directed against human cerebellar degeneration-related protein 2 (CDR2). Such antibodies may also be found in ovarian cancer patients without PCD. We studied if there was an association between Yo antibody production and differences in CDR2 cDNA sequence, mRNA or CDR2 expression in ovarian cancers. We found similar CDR2 cDNA sequence, mRNA and protein levels in primary ovarian cancers, with or without associated Yo antibodies. CDR2 was also present in other cancers, as well as in normal ovary tissue. The results suggest that Yo antibodies are not only related to the expression of CDR2 alone, but also to immune dysregulation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CDR2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution